DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for diabetes mellitus — screening already-approved drugs against its 37-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDiabetes mellitus maps to a 37-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for diabetes mellitus is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glucokinase (GCK) — GCK is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4DCH · 1.79 Å · ligand (2R)-3-cyclopentyl-2-[4-(methylsulfonyl)phenyl]-N-(1,3-thiazol-2-yl)propanamide (4DC). Experimental structure, not a prediction.
What the evidence adds up to
Diabetes mellitus is treatable but not curable, according to a 1964 paper. Management involves dietary restrictions and sometimes daily injections, and there is a significant risk of serious complications including blindness, gangrene, and renal failure. A 2014 paper states that despite improvements in treatments, many new and unresolved problems in pathogenesis and therapy remain; disease complications such as cardiovascular symptoms, vision impairments, nephropathy, and chronic leg infections are described as even more fatal than hyperglycaemia control. Drug toxicities from long-term use of chemical agents are noted as equally harmful for patients, and the paper reports that different doctors and drug manufacturers hold different views on treatment options and financial interests.
A 2024 review describes diabetes mellitus as a complex metabolic disorder characterised by high blood glucose from defects in insulin secretion, insulin action, or both, affecting millions worldwide and a leading cause of morbidity and mortality. The molecular mechanisms involve pancreatic beta-cell dysfunction, insulin resistance, and abnormalities in glucose, lipid, and protein metabolism, with contributions from genetic and environmental factors. The review states that targeting these mechanisms is important for developing new therapies, and that a better understanding can lead to more effective treatments and better disease management.
No drug is named in any of the three abstracts. No concrete numbers for survival, response rates, or sample sizes are provided. The 1964 paper explicitly states the disease is not curable, and the 2014 paper characterises current treatment as complicated and imperfect, noting drug toxicities and conflicting views among doctors and manufacturers.
What is still missing from the literature presented here is any specific drug candidate, any clinical trial data, any patient stratification strategy, and any funding for the new therapeutic systems or drug development pipelines that the 2014 paper proposes as future directions.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annals of Internal Medicine · 1964 · 18 citations
The Psychological Aspects of Diabetes.
AbstractDiabetes mellitus is treatable but not curable. Management is complex and involves dietary restrictions and sometimes daily injections. There is also a significant risk of serious complications which, at their worst, may include blindness, gangrene and renal failure. It is not surprising that a combination such as this may have significant psychological implications.
The Pathogenesis and Treatments of Diabetes, Questions and Answers
AbstractDiabetes Mellitus is an old disease but modern epidemics. Despite many improvements and benefits of diabetes mellitus treatments recently, many new and unresolved problems relevant to diabetes mellitus pathogenesis and therapy have been found; Pathogenesis and treatments study of diabetes currently is complicated and imperfect. Disease complications, such as cardiovascular symptoms, vision impairments, nephropathy, chronic leg infections etc are even more fatal than hyperglycemia control; Moreover, drug toxicities owing to long-term utilization of many chemical agents and drugs are equally harmful for patients. Furthermore, different doctors and drug manufactures hold different views on diabetes mellitus treatment options and financial interesting distributions. In this editorial, new ideas for building update diabetes mellitus therapeutic systems, new drug development pipelines and experimental and clinical models, possible future directions are proposed, addressed and highlighted.
AbstractDiabetes Mellitus (DM) is a complex metabolic disorder characterized by high blood glucose levels resulting from defects in insulin secretion, insulin action, or both. The disease affects millions worldwide and is a leading cause of morbidity and mortality. Molecular mechanisms underlying the pathogenesis of diabetes mellitus are complex and involve multiple cellular and molecular processes. In this review, we discuss the current understanding of the molecular mechanisms involved in the development and progression of diabetes mellitus. Specifically, we focus on the role of pancreatic beta-cell dysfunction, insulin resistance, and abnormalities in glucose metabolism, lipids, and proteins. We also examine the contribution of genetic and environmental factors to developing diabetes mellitus. Additionally, we highlight the importance of targeting these molecular mechanisms for developing new and effective therapies for managing diabetes mellitus. A better understanding of the molecular mechanisms involved in diabetes mellitus can lead to more effective treatments and better disease management.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
